With Pfizer’s stock down sharply, an activist investor is pushing for something new from the CEO who spurred the company to ...

Pfizer Inc. and Albert Bourla got the upper hand in an early skirmish against Starboard Value LP — but the drugmaker and its ...

As a long-term holding, Pfizer should benefit from demographic trends driving increased healthcare spending globally. The ...

Pfizer appointed a former chief executive officer at Vanguard, the drug giant's biggest investor, to its board on Tuesday as ...

The pharma will work with Triana Biomedicines on molecular glue degraders. Elsewhere, Akeso raised $250 million and a MASH ...

Pfizer Inc.’s stock gained Monday after a report that activist investor Starboard Value has invested $1 billion in the drug ...

The activist investment firm Starboard Value has launched a proxy fight again Pfizer, questioning the company’s management ...

Pfizer's stock is poised for growth with strong technical and fundamental indicators, promising pipeline, and Seagen ...

Pharma companies also are known for paying dividends, offering you a guaranteed stream of annual revenue. Below are three ...

Pfizer (PFE) stock may present opportunities for patient investors. Read how this biotech giant may deliver long-term ...

The FDA approved Pfizer’s Hympavzi, which can be an alternative to intravenous infusions often administered multiple times a ...

The approval of Hympavzi Friday was a dose of good news for Pfizer, which is dealing with research setbacks and a challenge from an activist investor.